Research & Development
OrganaBio and RxMP Therapeutics partner to advance RMP-402 haemostatic drug product
23 April 2026 - Blood and cell products and services company OrganaBio LLC and RxMP Therapeutics Inc, a late pre-clinical development stage therapeutics company developing novel therapies for the rapi...
Thryv Therapeutics doses first patients in Wave II clinical study for Long QT Syndrome; THRV-1268 receives FDA Fast Track Designation
23 April 2026 - Thryv Therapeutics Inc, a Canada-based, clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias...
WuXi Biologics receives South Korean certification for commercial manufacturing of bispecific antibody therapeutics
23 April 2026 - WuXi Biologics (HK:2269), a China-based global Contract Research, Development, and Manufacturing Organisation (CRDMO), announced on Thursday that three of its manufacturing facilities ...
Labcorp launches FDA-approved companion diagnostic to identify ovarian cancer patients' KEYTRUDA eligibility
23 April 2026 - US laboratory services provider Labcorp (NYSE:LH) announced on Wednesday the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion diagnostic...
European Commission approves Ojemda as first targeted therapy for relapsed paediatric low-grade glioma
22 April 2026 - French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Wednesday that the European Commission has granted conditional marketing authorisation for Ojemda (...
Renalytix advances kidneyintelX.Dkd scale-up with laboratory expansion and CE submission
22 April 2026 - Precision medicine diagnostics company Renalytix plc (LSE: RENX) (OTCQB: RNLXY) revealed on Wednesday that it has completed key regulatory and operational milestones to support the sca...